Literature DB >> 28026076

Ethical issues with colorectal cancer screening-a systematic review.

Bjørn Hofmann1,2.   

Abstract

RATIONALE, AIMS, AND
OBJECTIVES: Colorectal cancer (CRC) screening is widely recommended and implemented. However, sometimes CRC screening is not implemented despite good evidence, and some types of CRC screening are implemented despite lack of evidence. The objective of this article is to expose and elucidate relevant ethical issues in the literature on CRC screening that are important for open and transparent deliberation on CRC screening.
METHODS: An axiological question-based method is used for exposing and elucidating ethical issues relevant in HTA. A literature search in MEDLINE, Embase, PsycINFO, PubMed Bioethics subset, ISI Web of Knowledge, Bioethics Literature Database (BELIT), Ethics in Medicine (ETHMED), SIBIL Base dati di bioetica, LEWI Bibliographic Database on Ethics in the Sciences and Humanities, and EUROETHICS identified 870 references of which 114 were found relevant according to title and abstract. The content of the included papers were subject to ethical analysis to highlight the ethical issues, concerns, and arguments.
RESULTS: A wide range of important ethical issues were identified. The main benefits are reduced relative CRC mortality rate, and potentially incidence rate, but there is no evidence of reduced absolute mortality rate. Potential harms are bleeding, perforation, false test results, overdetection, overdiagnosis, overtreatment (including unnecessary removal of polyps), and (rarely) death. Other important issues are related to autonomy and informed choice equity, justice, medicalization, and expanding disease.
CONCLUSION: A series of important ethical issues have been identified and need to be addressed in open and transparent deliberation on CRC screening.
© 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  autonomy; axiology; benefits; colorectal cancer; deliberation; ethics; harms; screening

Mesh:

Year:  2016        PMID: 28026076     DOI: 10.1111/jep.12690

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  7 in total

1.  Overdiagnosis: one concept, three perspectives, and a model.

Authors:  Bjørn Hofmann; Lynette Reid; Stacy Carter; Wendy Rogers
Journal:  Eur J Epidemiol       Date:  2021-01-11       Impact factor: 8.082

2.  Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe.

Authors:  Esther Toes-Zoutendijk; Isabel Portillo; Sarah Hoeck; Isabel de Brabander; Philippe Perrin; Catherine Dubois; Monique van Leerdam; Iris Lansdorp-Vogelaar; Marc Bardou
Journal:  J Med Screen       Date:  2019-10-23       Impact factor: 2.136

3.  Psychosocial consequences of receiving false-positive colorectal cancer screening results: a qualitative study.

Authors:  Eva Lykke Toft; Sara Enggaard Kaae; Jessica Malmqvist; John Brodersen
Journal:  Scand J Prim Health Care       Date:  2019-05-11       Impact factor: 2.581

4.  The Role of Health Literacy in Explaining the Relation between Educational Level and Decision Making about Colorectal Cancer Screening.

Authors:  Anke J Woudstra; Ellen M A Smets; Mathilde G E Verdam; Mirjam P Fransen
Journal:  Int J Environ Res Public Health       Date:  2019-11-22       Impact factor: 3.390

5.  Different information needs-The major reasons for calling the helpline when invited to colorectal cancer screening.

Authors:  Kaisa Fritzell; Anders Kottorp; Anna Jervaeus
Journal:  Health Expect       Date:  2022-04-07       Impact factor: 3.318

6.  Evaluating facts and facting evaluations: On the fact-value relationship in HTA.

Authors:  Bjørn Hofmann; Ken Bond; Lars Sandman
Journal:  J Eval Clin Pract       Date:  2018-04-03       Impact factor: 2.431

7.  Psychometric properties of the SCREESCO questionnaire used in a colorectal cancer screening programme-A Rasch analysis.

Authors:  Anna Jervaeus; Kaisa Fritzell; Rolf Hultcrantz; Yvonne Wengström; Anders Kottorp
Journal:  J Eval Clin Pract       Date:  2019-11-22       Impact factor: 2.431

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.